Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To investigate the effects of the combination of berbamine (BBM) and ibrutinib on the proliferation and apoptosis of acute myeloid leukemia (AML) cells and the mechanism of combined action.
Methods: The AML cell lines were treated with BBM, ibrutinib and the combination of the two drugs respectively, CCK-8 method was used to detect the cell proliferation inhibition rate of each group and calculate the combination index (CI). The cell apoptosis in each group was detected by flow cytometry. Western blot was used to determine the expression of related proteins in each group.
Results: The cell viability in the combination group was significantly reduced, and the CI value of ED/ED/ED<1. The expression of apoptotic related protein in the combination group was significantly up-regulated, while the expression of p-BTK, p-AKT, CREB, GSK3β and BCL-XL were significantly down-regulated.
Conclusion: BBM and ibrutinib can synergistically inhibit the proliferation of AML cells and promote the apoptosis of AML cells. BBM and ibrutinib may play a synergistic effect through the p-BTK/p-AKT/CREB and GSK3β/BCL-XL signaling pathways.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2022.06.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab.
J Immunol
August 2025
Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States.
Immune checkpoint blockade has been shown to restore anti-tumor T-cell function and elicit durable responses in select solid and hematopoietic malignancies. However, single-agent anti-programmed death 1 (PD-1) antibodies proved less efficacious in patients with chronic lymphocytic leukemia (CLL). In patients with high-risk or relapsed/refractory CLL, we conducted a phase 2 study testing the combination of lead-in ibrutinib and up to 2 cycles of fludarabine, followed by continuous therapy with ibrutinib and 17 cycles of pembrolizumab administered every 3 weeks.
View Article and Find Full Text PDFBlockade of Bruton's tyrosine kinase suppresses B cell activation and antibody secretion in systemic lupus erythematosus.
Int Immunopharmacol
August 2025
Department of Transplantation, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electronic address:
Systemic lupus erythematosus (SLE) is an autoimmune disease with unsatisfactory clinical outcomes. The abnormal B cell activation and pathogenic antibodies secretion are important in the pathogenesis of SLE. Bruton's tyrosine kinase (BTK) plays vital roles in B cell activation, development and differentiation.
View Article and Find Full Text PDFDeep learning-driven drug response prediction and mechanistic insights in cancer genomics.
Sci Rep
July 2025
Pujiang People Institute, Shanghai, China.
In the field of cancer therapy, the diversity and heterogeneity of cancer genomes in clinical patients complicate and challenge the effective use of non-targeted drugs, as these drugs often fail to address specific genetic events. Recent advancements in large-scale in vitro drug screening assays have generated extensive drug testing and genomic data, providing valuable resources to explore the relationship between genomic features and drug responses. In this study, we developed a deep neural network model, DrugS (Drug Response prediction Utilizing Genomic features Screening), utilizing gene expression and drug testing data from human-derived cancer cell lines to predict cellular responses to drugs.
View Article and Find Full Text PDFExploring the potential function of high expression of in regulating ubiquitination in hepatocellular carcinoma.
World J Gastrointest Oncol
May 2025
Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Background: , a key regulator of the ubiquitination in tumour development, has not been thoroughly studied in hepatocellular carcinoma (HCC).
Aim: To elucidate the expression of in HCC and its potential regulatory mechanism related to ubiquitination.
Methods: Bulk RNA (RNA sequencing and microarrays), immunohistochemistry (IHC) tissues, and single-cell RNA sequencing (scRNA-seq) data were integrated to comprehensively investigate expression in HCC.
Effects of ibrutinib and venetoclax on the expression of immune checkpoint molecules in leukemic blasts of patients with acute lymphoblastic leukemia.
Biochem Biophys Rep
June 2025
Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Background: In recent decades, targeted therapy using small molecule inhibitors (SMI) have been shown very promising results in the treatment of a variety of solid and hematopoietic malignancies. However, their exact mechanisms, especiallay on the evasion strategies of tumor cells from the host immune system are not fully understood. The current study investigates the effects of two SMIs, ibrutinib and venetoclax, on the expression of inhibitory immune checkpoint molecules in patients with acute lymphoblastic leukemia (ALL).
View Article and Find Full Text PDF